For US Residents
KHONDAYA LogoKHONDAYA Logo
Phone IconPhone-icon
Call Us
Get access to the support you need in just 2-3 minutes.
See all thatNovartis Patient Supportcan offer:
Icon that looks like a hand holding a wallet
Financial Support
Provide you with financial support options. You could pay as little as $0 with the Co-Pay Plus* offer.
Icon of double shield
Insurance Support
Answer questions about your insurance coverage. We'll help you navigate the process.
Icon of a support person wearing a headset
Ongoing Support
Get useful tips, resources, and reminders throughout your treatment.
If you’d like to sign up on the phone, call 833-KHONDA1 (833-546-6321), Monday-Friday, 8:00 AM-8:00 PM ET (excluding holidays).
*
Co-Pay Plus Terms & Conditions: Offer valid only when used with commercial health insurance. Offer is not available where:
  • the patient has federal or state health plan benefits (eg, Medicare, Medicaid, TRICARE, VA);
  • the health plan reimburses for the entire cost of the drug;
  • the health plan provides no coverage for the drug; or
  • prohibited by law.
The amount of funding available from the Program is subject to an annual limit. Novartis reserves the right to discontinue the availability of co-pay assistance if, at any time, Novartis determines that the patient is subject to a co-pay maximizer program. Co-pay maximizers are programs implemented by health plans in which the amount of the patient’s out-of-pocket cost is increased to reflect the availability of support offered by a manufacturer assistance program. The patient is responsible for all costs once available funding from the Program is exhausted.
The Program is designed exclusively for the benefit of the patient. The amount of available funding may be reduced or eliminated if it is not credited by the patient’s health plan toward the patient’s out-of-pocket obligations (eg, deductibles, annual out-of-pocket maximums). Program funding may also be reduced or eliminated if the patient’s health plan, directly or indirectly, adjusts, reduces, or waives the patient’s health plan benefits based on the availability of, or the patient’s enrollment in, the Program, or otherwise acts in a manner that materially affects these Terms and Conditions.
Only the patient or their legal guardian or caregiver may enroll the patient in the Program. Health plans, specialty pharmacies, pharmacy benefit managers, and their agents and representatives (individually and collectively “Plan Administrators”), are prohibited from enrolling patients in the Program.
Patients in the Program are responsible for notifying Novartis of any change in their prescription drug health plan coverage that may conflict or otherwise affect compliance with these Terms and Conditions. By accepting Program funding from Novartis on behalf of participating patients, Plan Administrators agree to not take any action that materially affects compliance with these Terms and Conditions.
Patients may not seek reimbursement for the value received from the Program from any other party (eg, health plans, flexible spending or healthcare savings accounts). Patients are responsible for complying with any applicable limitations and requirements of their health plan related to their use of the Program.
Valid only in the United States and Puerto Rico.
The Program is not health insurance, and may not be combined with any third-party rebate, coupon, or offer. Novartis reserves the right to rescind, revoke, or amend the Program at any time without notice.
†

The Bridge Program applies to KHONDAYA only. Eligible patients must have private insurance and a valid prescription for KHONDAYA, and a delay or denial of coverage. Program requires the submission of a prior authorization and/or any other payer forms required for consideration of paid fill required as eligibility criteria, or an appeal of the coverage denial within the first 90 days of enrollment to remain eligible. Program provides KHONDAYA for free to eligible patients for up to 12 months, or until they receive insurance coverage approval, whichever occurs earlier. A valid prescription consistent with FDA-approved labeling is required. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Patients may be asked to reverify insurance coverage status during the course of the program. No purchase necessary. Program is not health insurance, nor is participation a guarantee of insurance coverage. Additional limitations may apply. Novartis Pharmaceuticals Corporation reserves the right to rescind, revoke, or amend this Program without notice.

5/26 FA-11607299

IMPORTANT SAFETY INFORMATION

What is KHONDAYA?

KHONDAYA is a prescription medicine that is used to treat adults with moderate to severe Sjögren’s disease. 

It is not known if KHONDAYA is safe and effective in children. 

Before using KHONDAYA, tell your healthcare provider about all of your medical conditions, including if you:

  • have ever experienced dizziness or fainting (low blood pressure), flushing, rash, fever, shortness of breath or feeling sick after a previous injection, or pain, redness and swelling at the site of injection (possible signs of general and local injection-related reactions or allergic reactions). Your healthcare provider may prescribe you medicines before the first injection of KHONDAYA to reduce your likelihood of getting a general injection-related reaction or allergic reaction.
  • suspect you may have an infection. Signs and symptoms of infection may include fever, sweats or chills, muscle aches, cough, shortness of breath, blood in your phlegm, weight loss, warm, red or painful skin or sores on your body, diarrhea or stomach pain, burning when you urinate or the need to urinate more often than normal. Your healthcare provider will check you for signs and symptoms of infections before you start your treatment with KHONDAYA. If you do have an infection, your healthcare provider may wait until it is resolved before giving you KHONDAYA.
  • plan to have a vaccination.
    • You should not be given ‘live’ or ‘live-attenuated’ vaccines during KHONDAYA treatment. These vaccines contain a living but weakened infectious agent.
    • You should be given ‘live’ or ‘live-attenuated’ vaccines at least 4 weeks before starting KHONDAYA.
    • Whenever possible, you should be given ‘non-live’ vaccines at least 2 weeks before starting KHONDAYA.
  • become pregnant during treatment and you plan to have your baby vaccinated, you should discuss this with your healthcare provider and/or with a specialist before having your baby vaccinated.
  • have or ever had a hepatitis B virus (HBV) infection or if you are a carrier of HBV. This is because KHONDAYA can cause HBV to become active again. Your healthcare provider will check if you are at risk of HBV infection before starting KHONDAYA.
    • If you have HBV infection, you may not be given KHONDAYA until the infection is resolved. Signs and symptoms of HBV infection may include worsening tiredness, yellowing of the skin or the white part of the eyes, dark urine, loss of appetite, nausea and/or pain in the upper right side of the abdomen.
    • If you have had hepatitis B or are a carrier of the HBV, you may be referred to a specialist before and during KHONDAYA treatment.
    • If you are a carrier of HBV, you may receive antiviral medicines before starting KHONDAYA treatment.
  • are pregnant, think that you might be pregnant, or plan to become pregnant. It is not known if KHONDAYA will harm your unborn baby.
    • You should use effective birth control (contraception) during treatment with KHONDAYA and for 6 months after your last injection of KHONDAYA. Talk to your healthcare provider about birth control methods that may be right for you.
    • Tell your healthcare provider right away if you become pregnant or think you may be pregnant while using KHONDAYA.
  • are breastfeeding or plan to breastfeed. It is not known if KHONDAYA passes into your breast milk. However, monoclonal antibodies, the group of medicines to which KHONDAYA belongs, are known to pass into breast milk. Your healthcare provider will discuss with you the benefits of breastfeeding for your baby and the benefits of KHONDAYA treatment for you.
  • Tell your healthcare provider about all the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, and herbal supplements.

How should I use KHONDAYA

  • Read the detailed “Instructions for Use” that comes with KHONDAYA for information about the right way to inject a dose of KHONDAYA and how to properly throw away (dispose of) used KHONDAYA prefilled syringes or pens.
  • Use KHONDAYA exactly as your healthcare provider tells you to use it. Do not stop KHONDAYA treatment unless your healthcare provider tells you that you can.
  • KHONDAYA is given by subcutaneous injection (injection under your skin).
  • The first injection should take place under the guidance of a healthcare provider. Your healthcare provider will show you or your caregiver how to inject KHONDAYA the right way before you or your caregiver use KHONDAYA for the first time.
  • You or your caregiver can give the injection into your abdomen or your thigh. Your caregiver can also inject KHONDAYA into the outer area of your upper arm. You or your caregiver should always use a different injection site to the one used for the previous dose.
  • Do not inject into areas where the skin is tender, bruised, red, scaly or hard. Avoid areas with scars or stretch marks.
  • Your healthcare provider may also give you other medicines before starting treatment with KHONDAYA.
  • If you forget an injection of KHONDAYA, inject yourself as soon as possible without waiting until the next scheduled dose. After that, give yourself the next injection 4 weeks later and continue at 4 week intervals.

What are the possible side effects of KHONDAYA?

The most common side effects of KHONDAYA include:

  • Fever, headache, chills, fatigue, joint pain, diarrhea, nausea, itching, rash (possible signs of general injection site reactions).
  • Redness, pain, itching and swelling at the injection site (possible signs of local injection site reactions)
  • Nose and throat infections (upper respiratory tract infections)
  • Fever, pain, redness, sore throat, and/or difficulty breathing (possible signs of low level of white blood cells, neutropenia) 

These are not all the possible side effects of KHONDAYA. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

INDICATION

KHONDAYA treat people 18 years of age and older with moderate to severe sjogrens disease.

5/26 FA-11607299